Literature DB >> 29257239

Elevated expression of PD‑1 on T cells correlates with disease activity in rheumatoid arthritis.

Qing Luo1, Jianqing Ye2, Lulu Zeng2, Zhongqin Luo1, Zhen Deng2, Xue Li2, Yang Guo1, Zikun Huang1, Junming Li1.   

Abstract

It is well known that lymphocytes are important in rheumatoid arthritis (RA). Programmed cell death-1 (PD‑1) is one of the immunosuppressive costimulatory molecules, which mediates an inhibitory effect. However, its role in RA remains to be fully elucidated. In the present study, the expression levels of PD‑1 on T cells in the peripheral blood (PB) and synovial fluid (SF) were determined using flow cytometry. In addition, the expression levels of PD‑1 on T cells in the PB and SF of patients with RA were further analyzed to determine correlation with markers of the autoimmune response, inflammation and disease activity in RA. Compared with healthy controls, the expression of PD‑1 on T cells in the PB was significantly elevated in patients with RA (P<0.0001). The expression of PD‑1 on T cells in the SF of patients with RA was significantly increased, compared with that in the autologous PB (P<0.0001). It was also found that the expression of PD‑1 on T cells in the PB of patients with RA was increased significantly in subjects with a high rheumatoid factor titer, high levels of inflammatory markers and a high disease activity score 28 (DAS28). The expression of PD‑1 on T cells in the SF of patients with RA was increased significantly in subjects with a high DAS28. These data showed that the expression of PD‑1 on T cells was elevated in patients with RA and was correlated with the disease activity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29257239     DOI: 10.3892/mmr.2017.8204

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  Analysis of PD-1 and Tim-3 expression on CD4+ T cells of patients with rheumatoid arthritis; negative association with DAS28.

Authors:  Zohreh Koohini; Hadi Hossein-Nataj; Maryam Mobini; Aref Hosseinian-Amiri; Alireza Rafiei; Hossein Asgarian-Omran
Journal:  Clin Rheumatol       Date:  2018-04-07       Impact factor: 2.980

2.  Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research.

Authors:  Celia Cartagena García; Nathalie Balandraud; Jean Roudier; Pierre Lafforgue; Nathalie Lambert; Jean-Marc Busnel
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

Review 3.  On Research Progress of Western and Chinese Medicine Treatment on Pre-Rheumatoid Arthritis.

Authors:  Xiang-Yu Kong; Cheng-Ping Wen
Journal:  Chin J Integr Med       Date:  2019-10-24       Impact factor: 1.978

4.  SAP interacts with CD28 to inhibit PD-1 signaling in T lymphocytes.

Authors:  Sabina Sandigursky; Mark R Philips; Adam Mor
Journal:  Clin Immunol       Date:  2020-06-03       Impact factor: 10.190

Review 5.  The PD-1:PD-L1 axis in Inflammatory Arthritis.

Authors:  Mary Canavan; Achilleas Floudas; Douglas J Veale; Ursula Fearon
Journal:  BMC Rheumatol       Date:  2021-01-11

Review 6.  Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions.

Authors:  Yan Mi; Jinming Han; Jie Zhu; Tao Jin
Journal:  Mol Neurobiol       Date:  2021-09-03       Impact factor: 5.590

7.  Programmed Cell Death Protein-1 Upregulation in Response to SARS-CoV-2 in Juvenile Idiopathic Arthritis: A Case-Control Study.

Authors:  Violetta Opoka-Winiarska; Ewelina Grywalska; Izabela Korona-Głowniak; Izabela Morawska; Krzysztof Gosik; Anna Malm; Jacek Roliński
Journal:  J Clin Med       Date:  2022-07-13       Impact factor: 4.964

8.  Increased TIGIT+PD‑1+CXCR5CD4+T cells are associated with disease activity in rheumatoid arthritis.

Authors:  Qing Luo; Peng Fu; Yongqin Guo; Biqi Fu; Yang Guo; Qingshui Huang; Zikun Huang; Junming Li
Journal:  Exp Ther Med       Date:  2022-08-31       Impact factor: 2.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.